Quarterly ResultMay 12, 2026, 08:07 AM
Mereo BioPharma Q1 Net Loss Halved to $6.7M; Cash $36.2M
AI Summary
Mereo BioPharma Group plc reported a significant reduction in its net loss for the first quarter of 2026, which decreased to $6.7 million from $12.9 million in the prior year. This improvement was primarily driven by lower general and administrative expenses and a favorable foreign currency transaction gain. The company ended the quarter with $36.2 million in cash and cash equivalents, down from $41.0 million at year-end 2025, and expects this to fund operations for at least 12 months.
Key Highlights
- Net loss for Q1 2026 decreased to $6.7 million from $12.9 million in Q1 2025.
- Loss per share improved to $(0.01) in Q1 2026 from $(0.02) in Q1 2025.
- Cash and cash equivalents were $36.2 million as of March 31, 2026.
- General and administrative expenses decreased to $4.0 million from $7.3 million year-over-year.
- Research and development expenses increased to $4.7 million from $3.9 million.
- Net cash used in operating activities reduced to $4.3 million from $8.3 million.
- Foreign currency transaction resulted in a $1.6 million gain in Q1 2026.
- Total shareholders' equity decreased to $34.1 million from $40.9 million at year-end 2025.
Price Impact
More from MREO